NCT03358277View on ClinicalTrials.gov

Aripiprazole Added on for DMDD in Youths With ADHD

NACompletedINTERVENTIONAL
Enrollment

58

Participants

Timeline

Start Date

November 19, 2014

Primary Completion Date

August 12, 2017

Study Completion Date

August 12, 2017

Conditions
Disruptive Mood Dysregulation Disorder
Interventions
DRUG

MPH + APZ

MPH was administered with either Ritalin (from 10mg/day to 40mg/day) or Concerta (from 18mg/day to 36mg/day) according to clinical judgement for six weeks. APZ was administered with dose from 2.5mg/day to 5mg/day according to clinical judgement for six weeks.

All Listed Sponsors
collaborator

Ministry of Science and Technology, Taiwan

OTHER_GOV

lead

Tri-Service General Hospital

OTHER

NCT03358277 - Aripiprazole Added on for DMDD in Youths With ADHD | Biotech Hunter | Biotech Hunter